

Receipt

APR 18 2000

CEDAR-043453

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Keith L. Black and Nagendra S. Ningaraj
Serial No. 09/491,500
Filed: January 26, 2000
For: METHOD FOR USING POTASSIUM CHANNEL AGONISTS
FOR DELIVERING A MEDICANT TO AN ABNORMAL BRAIN
REGION AND/OR A MALIGNANT TUMOR

Examiner: Unassigned
Unit: 1646

REQUEST FOR CORRECTION OF FILING RECEIPT

Application Processing Division
Customer Correction Branch
Assistant Secretary and Commissioner of
Patents and Trademarks
Washington, D. C. 20231

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN
ENVELOPE ADDRESSED TO APPLICATION PROCESSING DIVISION
CUSTOMER CORRECTION BRANCH THE ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D. C. 20231, ON April 5, 2000

BY Ann Weiss DATE April 5, 2000
Ann Weiss (DATE OF SIGNATURE)

Dear Sir or Madam:

Applicants request correction of Filing Receipt mailed March 27, 2000 with respect to the above-referenced application.

Applicants request that correct Filing Fee of \$1376 be indicated. Further, Applicant requests that Attorney Docket No. be corrected to indicate proper placement of hyphen as indicated on the filed application. Enclosed is a copy of the Filing Receipt mailed March 27, 2000 indicating corrections to be made.

Respectfully submitted,

PRETTY, SCHROEDER & POPLAWSKI, P.C.

By: Nisan

Nisan A. Steinberg, Ph.D.
Reg. No. 40,345

444 South Flower Street -19th Floor
Los Angeles, California 90071-2909
Ofc: 213/ 622-7700
Fax: 213/489-4210
18759.1

EG P/MAS

FILING RECEIPT



OC00000005011366



UNITED STATES DEPARTMENT OF


COMMERCE

Patent and Trademark Office

Address: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/491,500	01/26/2000	1646	1341 JUL 27 2000 C 76	CEDAR043-453 CEDAR-04353	3	109	8

Edward G Poplawski Esq
 Pretty Schroeder & Poplawski
 444 South Flower Street 19th Floor
 Los Angeles, CA 90071



DOCKETED

3/31/00 276

Date Mailed: 03/27/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Keith L Black, Los Angeles, CA ;
 Nagendra S Ningaraj, Culver City, CA ;

Continuing Data as Claimed by Applicant

Foreign Applications

If Required, Foreign Filing License Granted 03/27/2000

** SMALL ENTITY **

Title

Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor

Preliminary Class

424


Data entry by : WILSON, TAMMY

Team : OIPE

Date: 03/27/2000



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**



GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
 Office of Initial Patent Examination
 Customer Service Center
 Washington, DC 20231